Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis

Overview

Journal Arthritis Care Res (Hoboken)

Specialty Rheumatology

Date 2018 Oct 16

PMID 30320973

Citations 18

Authors

Tate M Johnson

Kyle A Register

Cynthia M Schmidt

James R ODell

Ted R Mikuls

Kaleb Michaud

Bryant R England

Affiliations

Soon will be listed here.

Abstract

Objective: There are conflicting reports on the validity of the multi-biomarker disease activity (MBDA) score for assessing rheumatoid arthritis (RA) disease activity. Our aim was to perform a systematic review of the MBDA and a meta-analysis of the correlation between the MBDA and other RA disease activity measures.

Methods: A systematic review was performed by searching Medline, Embase, Scopus, Google Scholar, and the Cochrane Library from inception to March 7, 2017. Study details, MBDA performance, and study quality were assessed by independent reviewers. Correlations of the MBDA with composite RA disease activity measures were pooled using random-effects meta-analyses.

Results: A total of 22 studies were identified in the systematic review, of which 8 (n = 3,242 assays) reported correlations of the MBDA with RA disease activity measures. Pooling results from these 8 studies in the meta-analysis, the MBDA demonstrated modest correlations with the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP; r = 0.41, 95% confidence interval [95% CI] 0.36-0.46) and the Disease Activity Score using the erythrocyte sedimentation rate (DAS28-ESR; r = 0.48, 95% CI 0.38-0.58), with weaker correlations observed with the Simplified Disease Activity Index (SDAI; r = 0.35, 95% CI 0.26-0.43), Clinical Disease Activity Index (CDAI; r = 0.26, 95% CI 0.19-0.33), and Routine Assessment of Patient Index Data 3 (RAPID3; r = 0.23, 95% CI 0.19-0.27). Correlations between change in MBDA and change in disease activity measures ranged from r = 0.53 for the DAS28-ESR to r = 0.26 for the CDAI.

Conclusion: The MBDA demonstrates moderate convergent validity with the DAS28-CRP and the DAS28-ESR but weaker correlations with the SDAI, CDAI, and RAPID3. While it appears to complement existing RA disease activity measures, further assessment of the performance characteristics of the MBDA is warranted.

Citing Articles

Decoding the Correlation Between Inflammatory Response Marker Interleukin-6 (IL-6) and C-reactive Protein (CRP) With Disease Activity in Rheumatoid Arthritis.

Warjukar P, Mohabey A, Jain P, Bandre G Cureus. 2024; 16(6):e62954.

PMID: 39050325 PMC: 11265957. DOI: 10.7759/cureus.62954.

Assessing the Impact of Influenza Vaccination Timing on Experimental Arthritis: Effects on Disease Progression and Inflammatory Biomarkers.

Tarjanyi V, Menes A, Hamid L, Kurucz A, Priksz D, Varga B Int J Mol Sci. 2024; 25(6).

PMID: 38542266 PMC: 10969894. DOI: 10.3390/ijms25063292.

Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care.

Al-Ewaidat O, Naffaa M Clin Exp Med. 2024; 24(1):30.

PMID: 38294723 PMC: 10830780. DOI: 10.1007/s10238-023-01288-7.

Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review.

Ward M, Madanchi N, Yazdanyar A, Shah N, Constantinescu F Arthritis Res Ther. 2023; 25(1):222.

PMID: 37986101 PMC: 10659063. DOI: 10.1186/s13075-023-03199-0.

Correlation between ultrasonographic scores and American college of rheumatology recommended rheumatoid arthritis disease activity measures: a systematic review and network meta-analysis.

Zhu J, Wang J, Dong Y, Song Y, Huang P J Ultrasound. 2023; 26(1):39-47.

PMID: 36633809 PMC: 10063773. DOI: 10.1007/s40477-022-00749-1.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Goswami R, Basu K, Das S, Mondal S, Ghosh P, Ghosh A . Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016; 75(7):e35. DOI: 10.1136/annrheumdis-2015-209094. View

Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan K . Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013; 8(4):e60635. PMC: 3621826. DOI: 10.1371/journal.pone.0060635. View

Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank S, Sasso E, Chernoff D . Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2014; 74(6):1102-9. PMC: 4431327. DOI: 10.1136/annrheumdis-2013-204986. View

van der Helm-van Mil A, Knevel R, Cavet G, Huizinga T, Haney D . An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford). 2013; 52(5):839-46. PMC: 3630394. DOI: 10.1093/rheumatology/kes378. View

Sokka T, Abelson B, Pincus T . Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008; 26(5 Suppl 51):S35-61. View

Hirata S, Li W, Defranoux N, Cavet G, Bolce R, Yamaoka K . A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Mod Rheumatol. 2014; 25(3):344-9. DOI: 10.3109/14397595.2014.958893. View

Curtis J, van der Helm-van Mil A, Knevel R, Huizinga T, Haney D, Shen Y . Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012; 64(12):1794-803. PMC: 3508159. DOI: 10.1002/acr.21767. View

Michaud K, Strand V, Shadick N, Degtiar I, Ford K, Michalopoulos S . Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. Rheumatology (Oxford). 2015; 54(9):1640-9. PMC: 4536857. DOI: 10.1093/rheumatology/kev023. View

10.

Reiss W, Devenport J, Low J, Wu G, Sasso E . Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. Rheumatol Int. 2015; 36(2):295-300. PMC: 4723630. DOI: 10.1007/s00296-015-3285-2. View

11.

Curtis J, Greenberg J, Harrold L, Kremer J, Palmer J . Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. Semin Arthritis Rheum. 2017; 47(4):472-477. DOI: 10.1016/j.semarthrit.2017.07.010. View

12.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006; 100(2):229-35. DOI: 10.1007/s10549-006-9242-8. View

13.

Li W, Sasso E, Emerling D, Cavet G, Ford K . Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Curr Med Res Opin. 2012; 29(1):85-92. DOI: 10.1185/03007995.2012.753042. View

14.

. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2016; 354:i4086. DOI: 10.1136/bmj.i4086. View

15.

Hambardzumyan K, Bolce R, Saevarsdottir S, Forslind K, Wallman J, Cruickshank S . Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. RMD Open. 2016; 2(1):e000197. PMC: 4780313. DOI: 10.1136/rmdopen-2015-000197. View

16.

Peabody J, Strand V, Shimkhada R, Lee R, Chernoff D . Impact of rheumatoid arthritis disease activity test on clinical practice. PLoS One. 2013; 8(5):e63215. PMC: 3646735. DOI: 10.1371/journal.pone.0063215. View

17.

Bakker M, Cavet G, Jacobs J, Bijlsma J, Haney D, Shen Y . Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012; 71(10):1692-7. PMC: 3439649. DOI: 10.1136/annrheumdis-2011-200963. View

18.

Zhao X, Qureshi F, Scott Eastman P, Manning W, Alexander C, Robinson W . Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis. J Immunol Methods. 2012; 378(1-2):72-80. PMC: 3404505. DOI: 10.1016/j.jim.2012.02.007. View

19.

Lee Y, Hackett J, Frits M, Iannaccone C, Shadick N, Weinblatt M . Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. Rheumatology (Oxford). 2015; 55(4):640-8. PMC: 4795537. DOI: 10.1093/rheumatology/kev388. View

20.

Keenan R, Swearingen C, Yazici Y . Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol. 2008; 26(5):814-9. View